News

Cell Therapeutics (CTI) and Spectrum established a joint venture in December 2008 to develop and commercialize Zevalin. At that time CTI contributed all of the Zevalin related assets

The purchase price per share was $1.15, which equaled the consolidated closing bid price of the company’s common stock as reported by the Nasdaq stock market on February

Crinobulin has shown promising vascular targeting activity with potent antitumor activity in both preclinical and early clinical studies, the company said. In preclinical in vitro and in vivo

Exactech said that its Optetrak RBK knee has been an important part of the company’s total knee business outside the US, particularly in Europe, where rotating bearing knee

The study had a composite primary efficacy endpoint: a clinically meaningful response in at least two of three endpoints in individual patients after the 52-week study period. The

Naftopidil dispersible tablets are used to treat benign enlargement of the prostate in middle-aged men. Peng Lai Jin Chuang Pharmaceutical will monitor and appraise Shaanxi Buchang Group’s sales

The trial, designated HVTN 205, is being conducted by the HIV Vaccine Trials Network (HVTN). The HVTN, funded and supported by the National Institutes of Allergy and Infectious

Prior to joining Sopherion, Dr Rozencweig was a key clinical development consultant to the company and a member of the Sopherion protocol development team for Myocet. Dr Rozencweig

The company also announced the first enrollment in its multi-center, randomized clinical trial of deep brain stimulation (DBS) for treatment-resistant depression. Medtronic is proceeding with the FDA investigational